SI2568049T1 - miši, ki izražajo hibridno lahko verigo imunoglobulina s humano spremenljivo regijo - Google Patents

miši, ki izražajo hibridno lahko verigo imunoglobulina s humano spremenljivo regijo

Info

Publication number
SI2568049T1
SI2568049T1 SI201130889A SI201130889A SI2568049T1 SI 2568049 T1 SI2568049 T1 SI 2568049T1 SI 201130889 A SI201130889 A SI 201130889A SI 201130889 A SI201130889 A SI 201130889A SI 2568049 T1 SI2568049 T1 SI 2568049T1
Authority
SI
Slovenia
Prior art keywords
light chain
variable region
human variable
mice expressing
hybrid light
Prior art date
Application number
SI201130889A
Other languages
English (en)
Inventor
Lynn Macdonald
Sean Stevens
Cagan Gurer
Andrew J. Murphy
Karolina A. Hosiawa
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of SI2568049T1 publication Critical patent/SI2568049T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
SI201130889A 2010-06-22 2011-06-22 miši, ki izražajo hibridno lahko verigo imunoglobulina s humano spremenljivo regijo SI2568049T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35731410P 2010-06-22 2010-06-22
US35731710P 2010-06-22 2010-06-22
EP12195716.1A EP2568049B1 (en) 2010-06-22 2011-06-22 Mice expressing an immunoglobulin hybrid light chain with a human variable region

Publications (1)

Publication Number Publication Date
SI2568049T1 true SI2568049T1 (sl) 2016-10-28

Family

ID=44509861

Family Applications (5)

Application Number Title Priority Date Filing Date
SI201131325T SI2905338T1 (sl) 2010-06-22 2011-06-22 Transgene miši z modificiranim endogenim lambda imunoglobulinskim lokusom
SI201130889A SI2568049T1 (sl) 2010-06-22 2011-06-22 miši, ki izražajo hibridno lahko verigo imunoglobulina s humano spremenljivo regijo
SI201130810A SI2480676T1 (sl) 2010-06-22 2011-06-22 Hibridna mišja lahka veriga
SI201130867A SI2480675T1 (sl) 2010-06-22 2011-06-22 Miši, ki izražajo lahko verigo s spremenljivo regijo humanega lambda in konstantno mišjo regijo
SI201131716T SI3034608T1 (sl) 2010-06-22 2011-06-22 Miši, ki izražajo hibridno lahko verigo imunoglobulina s humano variabilno regijo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201131325T SI2905338T1 (sl) 2010-06-22 2011-06-22 Transgene miši z modificiranim endogenim lambda imunoglobulinskim lokusom

Family Applications After (3)

Application Number Title Priority Date Filing Date
SI201130810A SI2480676T1 (sl) 2010-06-22 2011-06-22 Hibridna mišja lahka veriga
SI201130867A SI2480675T1 (sl) 2010-06-22 2011-06-22 Miši, ki izražajo lahko verigo s spremenljivo regijo humanega lambda in konstantno mišjo regijo
SI201131716T SI3034608T1 (sl) 2010-06-22 2011-06-22 Miši, ki izražajo hibridno lahko verigo imunoglobulina s humano variabilno regijo

Country Status (31)

Country Link
US (21) US9035128B2 (sl)
EP (7) EP3034608B1 (sl)
JP (15) JP6009441B2 (sl)
KR (16) KR101934852B1 (sl)
CN (4) CN104342455B (sl)
AU (1) AU2011271046B2 (sl)
BR (3) BR112012033248A2 (sl)
CA (2) CA2804311C (sl)
CY (5) CY1117537T1 (sl)
DK (5) DK2480676T3 (sl)
ES (5) ES2575223T3 (sl)
HK (4) HK1168384A1 (sl)
HR (5) HRP20160497T1 (sl)
HU (5) HUE036597T2 (sl)
IL (11) IL300712A (sl)
LT (4) LT2480675T (sl)
ME (5) ME02440B (sl)
MX (6) MX348942B (sl)
MY (6) MY195212A (sl)
NO (1) NO2905338T3 (sl)
NZ (6) NZ707198A (sl)
PL (5) PL3034608T3 (sl)
PT (5) PT3034608T (sl)
RS (5) RS55037B1 (sl)
RU (3) RU2724736C2 (sl)
SG (4) SG10201504324UA (sl)
SI (5) SI2905338T1 (sl)
SM (3) SMT201600212B (sl)
TR (1) TR201905992T4 (sl)
WO (2) WO2011163314A1 (sl)
ZA (5) ZA201300062B (sl)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
EP3889265A1 (en) 2008-09-30 2021-10-06 Ablexis, LLC Transgenic mice for the production of chimeric antibodies
JP5827127B2 (ja) 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
PT2517556E (pt) 2009-07-08 2016-01-20 Kymab Ltd Modelos animais e moléculas terapêuticas
LT3095871T (lt) 2010-02-08 2019-05-27 Regeneron Pharmaceuticals, Inc. Bendros lengvosios grandinės pelė
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
AU2011234988B2 (en) 2010-03-31 2014-10-30 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
BR112012033248A2 (pt) 2010-06-22 2017-11-28 Regeneron Pharma camundongos expressando uma cadeia leve com variável de lâmbda humana e regiões constantes de camundongo
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
CN103025884B (zh) 2010-07-26 2015-11-25 特里安尼公司 转基因动物和使用方法
SG10201912639SA (en) 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
US10130081B2 (en) 2011-08-05 2018-11-20 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR101924805B1 (ko) 2011-12-20 2018-12-04 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
AU2013204581B2 (en) 2012-03-16 2015-06-25 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
CN104302169B (zh) 2012-03-16 2017-11-17 瑞泽恩制药公司 组氨酸工程改造的轻链抗体和用于生成所述抗体的经基因修饰的非人动物
RS59076B1 (sr) 2012-03-16 2019-09-30 Regeneron Pharma Glodari koji eksprimiraju imunoglobulinske sekvence senzitivne na ph
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
JP2015512635A (ja) 2012-03-28 2015-04-30 カイマブ・リミテッド クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
TR201810255T4 (tr) 2013-02-20 2018-08-27 Regeneron Pharma Modifiye edilmiş immunoglobulin ağır zincir sekanslarına sahip olan insan olmayan hayvanlar.
FI3501272T3 (fi) * 2013-03-13 2023-04-06 Regeneron Pharma Rajallista immunoglobuliinin kevytketjuvalikoimaa ilmentäviä hiiriä
WO2014141189A1 (en) 2013-03-14 2014-09-18 Erasmus University Medical Center Transgenic non-human mammal for antibody production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
CN111019953A (zh) * 2013-09-18 2020-04-17 瑞泽恩制药公司 组氨酸工程改造的轻链抗体和用于生成所述抗体的经基因修饰的非人动物
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
EP3092007A4 (en) * 2014-01-10 2017-06-07 Allermabs Co. Ltd. Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
CA3124228A1 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
MX2016012273A (es) * 2014-03-21 2017-02-23 Regeneron Pharma Proteinas de union al antigeno vl que presentan diferentes caracteristicas de union.
SG10201810507WA (en) 2014-06-06 2018-12-28 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
BR112017005245A2 (pt) 2014-09-19 2017-12-12 Regeneron Pharma animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos.
JP2017531642A (ja) 2014-10-03 2017-10-26 マサチューセッツ インスティテュート オブ テクノロジー エボラ糖タンパク質に結合する抗体およびその使用
EP3725808A1 (en) 2014-11-21 2020-10-21 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
AU2015365583B2 (en) 2014-12-19 2021-10-28 Regenesance B.V. Antibodies that bind human C6 and uses thereof
BR112017013385A2 (pt) 2014-12-23 2018-02-06 Bristol-Myers Squibb Company anticorpos para tigit
AU2016214399B2 (en) 2015-02-05 2020-01-16 Basf Se Solar power plant comprising a first heat transfer circuit and a second heat transfer circuit
CN107438622A (zh) * 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
JP2018526977A (ja) 2015-06-29 2018-09-20 ザ ロックフェラー ユニヴァーシティ アゴニスト活性が増強されたｃｄ４０に対する抗体
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
US11213586B2 (en) 2015-11-19 2022-01-04 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
CA3012833A1 (en) 2016-02-04 2017-08-10 Trianni, Inc. Enhanced production of immunoglobulins
EA201891983A8 (ru) 2016-03-04 2020-05-28 Бристол-Майерс Сквибб Компани Комбинированная терапия антителами к cd73
EP3423489A1 (en) 2016-03-04 2019-01-09 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
KR102417687B1 (ko) 2016-05-09 2022-07-07 브리스톨-마이어스 스큅 컴퍼니 Tl1a 항체 및 그의 용도
WO2017201476A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
PL3462853T3 (pl) 2016-06-03 2023-06-26 Regeneron Pharmaceuticals, Inc. Gryzonie wykazujące ekspresję egzogennej terminalnej transferazy deoksynukleotydowej
WO2017214089A1 (en) * 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
US10650241B2 (en) * 2016-06-27 2020-05-12 Facebook, Inc. Systems and methods for identifying matching content
JP7027401B2 (ja) 2016-07-14 2022-03-01 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
CN109996560A (zh) 2016-10-13 2019-07-09 麻省理工学院 结合寨卡病毒包膜蛋白的抗体及其用途
HRP20220888T1 (hr) * 2016-11-04 2022-10-28 Regeneron Pharmaceuticals, Inc. Ne-humane životinje koje imaju konstruirani lokus imunoglobulinskog lamba lakog lanca
BR112019016374A2 (pt) 2017-02-17 2020-04-07 Bristol-Myers Squibb Company anticorpos para alfa-sinucleína e usos dos mesmos
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
KR20200093570A (ko) 2017-12-05 2020-08-05 리제너론 파마슈티칼스 인코포레이티드 조작된 면역글로불린 람다 경쇄를 갖는 비-인간 동물 및 그의 용도
US20220089720A1 (en) 2018-01-12 2022-03-24 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
CN111886256A (zh) 2018-03-23 2020-11-03 百时美施贵宝公司 抗mica和/或micb抗体及其用途
RU2020131383A (ru) 2018-03-24 2022-04-26 Ридженерон Фармасьютикалз, Инк. Генетически модифицированные животные, отличные от человека, для выработки терапевтических антител против комплексов пептид-mhc, способы их получения и варианты применения
JP7328243B2 (ja) 2018-03-26 2023-08-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療薬を試験するためのヒト化げっ歯類
EP3813521A4 (en) * 2018-06-08 2022-02-23 Crystal Bioscience Inc. TRANSGENIC ANIMAL TO PRODUCE DIVERSIFIED ANTIBODIES HAVING THE SAME LIGHT CHAIN II
PL3629720T3 (pl) 2018-06-14 2022-05-02 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż człowiek zdolne do rearanżacji dh-dh w sekwencjach kodujących łańcucha ciężkiego immunoglobuliny
JPWO2020085011A1 (ja) 2018-10-26 2021-10-14 ビークルエナジージャパン株式会社 電池制御装置
EP3880708A1 (en) 2018-11-16 2021-09-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
CA3127236A1 (en) 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
EP3927153A1 (en) 2019-02-22 2021-12-29 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
AU2020289554A1 (en) * 2019-06-05 2021-11-18 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
AU2020298458A1 (en) * 2019-07-01 2022-01-20 Trianni, Inc. Transgenic mammals and methods of use thereof
CN114901678A (zh) 2019-12-02 2022-08-12 瑞泽恩制药公司 肽-mhc ii蛋白构建体及其用途
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
AU2020454777A1 (en) * 2020-06-25 2023-02-02 Humab Co., Ltd. Heterozygous transgenic animal
WO2022056276A1 (en) 2020-09-11 2022-03-17 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
KR20230147048A (ko) 2020-12-16 2023-10-20 리제너론 파마슈티칼스 인코포레이티드 인간화 Fc 알파 수용체를 발현하는 마우스
TW202242114A (zh) 2020-12-23 2022-11-01 美商再生元醫藥公司 用於獲得結合至跨膜蛋白之抗體以及抗體生成細胞的方法
US20220195014A1 (en) 2020-12-23 2022-06-23 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
IE921169A1 (en) 1991-04-10 1992-10-21 Scripps Research Inst Heterodimeric receptor libraries using phagemids
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
KR100643058B1 (ko) * 1996-12-03 2006-11-13 아브게닉스, 인크. 복수의 Ｖн 및 Ｖк 영역을 함유하는 인간 면역글로불린 유전자좌를 갖는 트랜스제닉 포유동물 및 이로부터 생성된 항체
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) * 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
EP1391511B1 (en) * 2001-05-11 2008-06-11 Kirin Pharma Kabushiki Kaisha Artificial human chromosome containing human antibody lambda light chain gene
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
DK1461442T3 (en) 2001-11-30 2017-12-04 Amgen Fremont Inc Transgenic animals with human Ig lambda light chain genes
US20030217171A1 (en) 2002-05-17 2003-11-20 Von Stuermer Wolfgang R. Self-replicating and self-installing software apparatus
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
CN1605628A (zh) * 2003-09-03 2005-04-13 中国疾病预防控制中心病毒病预防控制所 Cho细胞生产的人源抗甲肝病毒基因工程抗体
RS51326B (sr) * 2004-08-05 2010-12-31 Genentech Inc. Humanizovani anti-cmet antagonisti
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
CN101111521B (zh) * 2004-12-29 2011-08-24 株式会社柳韩洋行 肿瘤坏死因子-α特异性人源化抗体
JP5514539B2 (ja) 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
US8084024B2 (en) * 2006-08-22 2011-12-27 G2 Inflammation Pty Ltd Method for producing antibodies
MY149079A (en) * 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
US7864492B2 (en) 2006-10-31 2011-01-04 Siemens Industry, Inc. Systems and methods for arc fault detection
DE102007045897A1 (de) 2007-09-26 2009-04-09 Carl Zeiss Microimaging Gmbh Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe
US8012714B2 (en) * 2008-04-14 2011-09-06 Innovative Targeting Solutions, Inc. Sequence diversity generation in immunoglobulins
ES2436044T3 (es) 2008-05-23 2013-12-26 Ablexis, Llc Procedimiento de generación de anticuerpos de dominio VL individual en animales transgénicos
EP3889265A1 (en) 2008-09-30 2021-10-06 Ablexis, LLC Transgenic mice for the production of chimeric antibodies
JP5827127B2 (ja) * 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
PT2517556E (pt) 2009-07-08 2016-01-20 Kymab Ltd Modelos animais e moléculas terapêuticas
LT3095871T (lt) * 2010-02-08 2019-05-27 Regeneron Pharmaceuticals, Inc. Bendros lengvosios grandinės pelė
CN103228130B (zh) 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
BR112012033248A2 (pt) 2010-06-22 2017-11-28 Regeneron Pharma camundongos expressando uma cadeia leve com variável de lâmbda humana e regiões constantes de camundongo

Also Published As

Publication number Publication date
US20150320023A1 (en) 2015-11-12
US20150173332A1 (en) 2015-06-25
US20150176002A1 (en) 2015-06-25
CY1117537T1 (el) 2017-04-26
US9540452B2 (en) 2017-01-10
AU2011271043A1 (en) 2013-01-31
US9394373B2 (en) 2016-07-19
EP3034608B1 (en) 2019-01-30
SG10201504568YA (en) 2015-07-30
JP6963542B2 (ja) 2021-11-10
KR102118565B1 (ko) 2020-06-03
US20130326647A1 (en) 2013-12-05
PT3034608T (pt) 2019-05-28
SMT201600229B (sl) 2016-08-31
MX2012015300A (es) 2013-05-01
KR20200064166A (ko) 2020-06-05
PL2480676T3 (pl) 2016-10-31
EP3456832A1 (en) 2019-03-20
MY195214A (en) 2023-01-11
KR102059909B1 (ko) 2019-12-27
JP2018023403A (ja) 2018-02-15
MY195212A (en) 2023-01-11
KR20180135997A (ko) 2018-12-21
JP2018201528A (ja) 2018-12-27
ME02902B (me) 2018-04-20
NZ605751A (en) 2014-10-31
NZ707198A (en) 2016-04-29
ZA201300062B (en) 2014-09-25
PL3034608T3 (pl) 2019-08-30
IL269078A (en) 2019-11-28
MX347322B (es) 2017-04-21
HUE029692T2 (en) 2017-03-28
JP2013532974A (ja) 2013-08-22
CN104404050A (zh) 2015-03-11
EP2905338B8 (en) 2018-01-24
KR20190049932A (ko) 2019-05-09
HRP20160497T1 (hr) 2016-07-15
EP2568049B1 (en) 2016-04-13
IL300712A (en) 2023-04-01
HK1170766A1 (zh) 2013-03-08
IL269078B (en) 2021-05-31
IL282872B (en) 2022-04-01
KR20210073609A (ko) 2021-06-18
KR101975884B1 (ko) 2019-05-10
LT3034608T (lt) 2019-05-27
JP5988969B2 (ja) 2016-09-07
DK2480675T3 (en) 2016-08-01
US20190203171A1 (en) 2019-07-04
US20190153384A1 (en) 2019-05-23
WO2011163314A1 (en) 2011-12-29
JP2020062061A (ja) 2020-04-23
CN103068993A (zh) 2013-04-24
JP2020128440A (ja) 2020-08-27
IL247386A (en) 2017-07-31
US20140137275A1 (en) 2014-05-15
RU2013102595A (ru) 2014-07-27
ZA201404601B (en) 2016-02-24
US20120070861A1 (en) 2012-03-22
MX336344B (es) 2016-01-15
KR20190014578A (ko) 2019-02-12
EP2480675B1 (en) 2016-04-06
MX347318B (es) 2017-04-21
IL259965B (en) 2019-02-28
US20170258059A1 (en) 2017-09-14
MY165287A (en) 2018-03-21
CY1119478T1 (el) 2018-03-07
KR101934852B1 (ko) 2019-01-04
MX2022002117A (es) 2022-03-17
CA2803864C (en) 2017-05-16
US20160060359A1 (en) 2016-03-03
DK2480676T3 (en) 2016-06-20
IL255179A0 (en) 2017-12-31
DK2568049T3 (en) 2016-08-01
DK3034608T3 (da) 2019-05-06
RS55042B1 (sr) 2016-12-30
SG186391A1 (en) 2013-01-30
BR112012033248A2 (pt) 2017-11-28
ME02440B (me) 2016-09-20
US20150351371A1 (en) 2015-12-10
KR20180135996A (ko) 2018-12-21
SI2905338T1 (sl) 2017-12-29
ES2570131T3 (es) 2016-05-17
JP2013531501A (ja) 2013-08-08
EP2480675A1 (en) 2012-08-01
JP7236409B2 (ja) 2023-03-09
RS55037B1 (sr) 2016-12-30
MY195217A (en) 2023-01-11
PL2480675T3 (pl) 2017-03-31
PT2568049T (pt) 2016-07-11
CA2804311A1 (en) 2011-12-29
KR20200143511A (ko) 2020-12-23
BR122020013427B1 (pt) 2021-08-03
EP2905338B1 (en) 2017-08-02
US20150173331A1 (en) 2015-06-25
PL2568049T3 (pl) 2017-03-31
EP2905338A1 (en) 2015-08-12
RS58736B1 (sr) 2019-06-28
RU2601297C2 (ru) 2016-10-27
US20160057979A1 (en) 2016-03-03
AU2011271043A8 (en) 2016-01-21
US9006511B2 (en) 2015-04-14
MY194456A (en) 2022-11-30
AU2011271043B2 (en) 2015-10-01
KR102462042B1 (ko) 2022-11-03
HUE030285T2 (en) 2017-05-29
PT2480675T (pt) 2016-07-11
BR112012032991B1 (pt) 2021-08-10
ME02444B (me) 2016-09-20
KR101945352B1 (ko) 2019-02-07
US20150246977A1 (en) 2015-09-03
JP2021061863A (ja) 2021-04-22
ZA201404600B (en) 2015-09-30
KR20190142436A (ko) 2019-12-26
US9163092B2 (en) 2015-10-20
RU2590594C2 (ru) 2016-07-10
AU2011271046B2 (en) 2015-10-01
KR20230036157A (ko) 2023-03-14
JP6009441B2 (ja) 2016-10-19
KR101991234B1 (ko) 2019-06-20
BR112012032991A8 (pt) 2020-09-29
NZ627119A (en) 2015-05-29
ES2646052T3 (es) 2017-12-11
ES2575223T3 (es) 2016-06-27
IL264634B (en) 2019-09-26
IL291301B2 (en) 2023-07-01
CN104404050B (zh) 2018-06-08
EP3034608A1 (en) 2016-06-22
EP3205726A1 (en) 2017-08-16
HUE029691T2 (en) 2017-03-28
MY157477A (en) 2016-06-15
JP2017012204A (ja) 2017-01-19
US20120073004A1 (en) 2012-03-22
WO2011163311A1 (en) 2011-12-29
SI2480676T1 (sl) 2016-10-28
CN103068993B (zh) 2016-01-06
JP2018201527A (ja) 2018-12-27
US9844212B2 (en) 2017-12-19
RS54891B1 (sr) 2016-10-31
KR102266097B1 (ko) 2021-06-18
PT2905338T (pt) 2017-11-10
DK2905338T3 (da) 2017-11-06
KR20190073584A (ko) 2019-06-26
SMT201600212B (it) 2016-08-31
HRP20171666T1 (hr) 2017-12-15
NZ605758A (en) 2014-08-29
HK1183321A1 (zh) 2013-12-20
US9035128B2 (en) 2015-05-19
TR201905992T4 (tr) 2019-05-21
PT2480676E (pt) 2016-06-09
CA2803864A1 (en) 2011-12-29
JP2016010415A (ja) 2016-01-21
HRP20190807T1 (hr) 2019-08-23
HUE044001T2 (hu) 2019-09-30
KR20220150430A (ko) 2022-11-10
US20150246976A1 (en) 2015-09-03
MX348942B (es) 2017-07-04
EP2480676A1 (en) 2012-08-01
CY1117692T1 (el) 2017-05-17
JP6243384B2 (ja) 2017-12-06
JP6545773B2 (ja) 2019-07-17
KR101970944B1 (ko) 2019-04-23
IL244450A0 (en) 2016-04-21
US9029628B2 (en) 2015-05-12
KR20210134424A (ko) 2021-11-09
ZA201300063B (en) 2014-09-25
CY1118126T1 (el) 2017-06-28
RU2013102596A (ru) 2014-07-27
AU2011271043A9 (en) 2015-10-01
IL259965A (en) 2018-07-31
KR102001430B1 (ko) 2019-07-18
HK1226766A1 (zh) 2017-10-06
IL291301A (en) 2022-05-01
CN103068994B (zh) 2016-01-20
HRP20160865T1 (hr) 2016-10-07
IL223720A (en) 2017-05-29
MX2012015298A (es) 2013-05-01
US9206263B2 (en) 2015-12-08
ME03386B (me) 2020-01-20
US20130323790A1 (en) 2013-12-05
BR112012032991A2 (pt) 2015-10-06
IL282872A (en) 2021-06-30
IL291301B1 (en) 2023-03-01
KR102506001B1 (ko) 2023-03-07
RU2016119423A3 (sl) 2019-11-19
US9850462B2 (en) 2017-12-26
IL223719A (en) 2016-10-31
US20180064078A1 (en) 2018-03-08
KR20210013376A (ko) 2021-02-03
PL2905338T3 (pl) 2018-01-31
US20170107484A1 (en) 2017-04-20
KR20130121814A (ko) 2013-11-06
LT2568049T (lt) 2016-10-10
KR102193823B1 (ko) 2020-12-22
US20150089680A1 (en) 2015-03-26
JP2022066449A (ja) 2022-04-28
SI2480675T1 (sl) 2016-08-31
CY1122877T1 (el) 2021-05-05
KR20190014576A (ko) 2019-02-12
RU2016119423A (ru) 2018-11-07
CN104342455A (zh) 2015-02-11
CA2804311C (en) 2017-09-12
JP6073441B2 (ja) 2017-02-01
US9012717B2 (en) 2015-04-21
US9066502B2 (en) 2015-06-30
JP6341972B2 (ja) 2018-06-13
HUE036597T2 (hu) 2018-07-30
US9206261B2 (en) 2015-12-08
NZ707200A (en) 2016-04-29
JP2023133554A (ja) 2023-09-22
ME02442B (me) 2016-09-20
US9150662B2 (en) 2015-10-06
KR102320944B1 (ko) 2021-11-04
SI3034608T1 (sl) 2019-06-28
US9334333B2 (en) 2016-05-10
ES2721749T3 (es) 2019-08-05
HK1168384A1 (zh) 2012-12-28
EP2568049A1 (en) 2013-03-13
CN103068994A (zh) 2013-04-24
LT2905338T (lt) 2017-12-27
RS56589B1 (sr) 2018-02-28
CN104342455B (zh) 2017-05-31
JP2019033765A (ja) 2019-03-07
US9226484B2 (en) 2016-01-05
US20200239837A1 (en) 2020-07-30
JP2016010417A (ja) 2016-01-21
LT2480675T (lt) 2016-10-10
SMT201600213B (it) 2016-08-31
AU2011271046A1 (en) 2013-01-31
RU2724736C2 (ru) 2020-06-25
US10266803B2 (en) 2019-04-23
SG186390A1 (en) 2013-01-30
US9206262B2 (en) 2015-12-08
NO2905338T3 (sl) 2017-12-30
EP2480676B1 (en) 2016-04-06
KR20130027555A (ko) 2013-03-15
ZA201506598B (en) 2017-03-29
KR102211911B1 (ko) 2021-02-05
JP2017006152A (ja) 2017-01-12
HRP20160794T1 (hr) 2016-08-12
US9399683B2 (en) 2016-07-26
IL244450A (en) 2017-11-30
ES2576928T3 (es) 2016-07-12
IL255179B (en) 2018-06-28
NZ626979A (en) 2015-05-29
SG10201504324UA (en) 2015-07-30

Similar Documents

Publication Publication Date Title
HRP20160865T1 (hr) Miš koji izražava hibridni laki lanac imunoglobulina s humanom varijabilnom regijom
SG11201405058WA (en) Animals expressing human lambda immunoglobulin light chain variable domain
ZA201505835B (en) Mice expressing a limited immunoglobulin light chain reperoire
EP2643768A4 (en) HETEROGENEOUS FILE OPTIMIZATION
PL2384180T3 (pl) Powłoka pieluchy
GB2481036B (en) A vehicle light and a vehicle including at least one vehicle light
GB201004506D0 (en) Light snack
PT2384180E (pt) Capa de fralda